Key Takeaways
- • Trevi Therapeutics raises $150M through the sale of more than 11.5 million shares at $13 per share, positioning the company to advance clinical development of its respiratory pipeline.
- • Trevi advancing Haduvio toward Phase 3 trial in IPF-related cough in Q2 2026, with the candidate also in development for non-IPF interstitial lung disease and refractory chronic cough indications.
- • Spain-Boston biotech venture capital fund launched with an initial target size of $200 million, with Spain committing $57 million to scale Spanish life science companies located in Boston, according to Spain's Minister of Economy, Trade and Business Carlos Cuerpo.
- • UK clinical trial setup accelerates significantly, with median timeline reduced from 169 days to 122 days year-over-year, supporting the government's goal to complete trial setup within 150 days by March 2027 and enhance the UK's biotech investment attractiveness.
Summary
Trevi Therapeutics announced a $150 million equity raise through a public share offering, selling more than 11.5 million shares at $13 per share. The capital raise reflects investor confidence in the company's respiratory disease pipeline and supports advancement of its lead candidate, Haduvio, which addresses significant unmet needs across multiple indications including idiopathic pulmonary fibrosis (IPF)-related cough, non-IPF interstitial lung disease, and refractory chronic cough. Trevi plans to initiate a Phase 3 trial for Haduvio in IPF-related cough during the second quarter of 2026, representing a critical milestone in the company's clinical development strategy.
In a separate development signaling renewed momentum in biotech fund formation, Spain and Boston announced the launch of a collaborative venture capital fund targeting $200 million in initial capitalization. Spain is committing $57 million directly to the fund, which remains open to additional private investors. According to Carlos Cuerpo, Spain's Minister of Economy, Trade and Business, the fund's primary objective is to scale Spanish life science companies with operations in Boston, creating a bridge between European innovation and North American life sciences infrastructure and capital markets.
Additionally, the UK regulatory environment for clinical trials demonstrated measurable improvement. The Department of Health and Social Care reported that the median timeline to establish a UK clinical trial has compressed from 169 days to 122 days when comparing the first half of 2026 to the prior year period. This 47-day reduction aligns with Prime Minister Keir Starmer's stated objective to establish clinical studies within 150 days by March 2027. Accelerating trial setup timelines is a strategic priority for the UK government as it works to enhance the country's competitiveness for biopharmaceutical investment and facilitate faster drug development and regulatory approvals.
In a separate development signaling renewed momentum in biotech fund formation, Spain and Boston announced the launch of a collaborative venture capital fund targeting $200 million in initial capitalization. Spain is committing $57 million directly to the fund, which remains open to additional private investors. According to Carlos Cuerpo, Spain's Minister of Economy, Trade and Business, the fund's primary objective is to scale Spanish life science companies with operations in Boston, creating a bridge between European innovation and North American life sciences infrastructure and capital markets.
Additionally, the UK regulatory environment for clinical trials demonstrated measurable improvement. The Department of Health and Social Care reported that the median timeline to establish a UK clinical trial has compressed from 169 days to 122 days when comparing the first half of 2026 to the prior year period. This 47-day reduction aligns with Prime Minister Keir Starmer's stated objective to establish clinical studies within 150 days by March 2027. Accelerating trial setup timelines is a strategic priority for the UK government as it works to enhance the country's competitiveness for biopharmaceutical investment and facilitate faster drug development and regulatory approvals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.